465 related articles for article (PubMed ID: 12431053)
1. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Sterling J; Herzig Y; Goren T; Finkelstein N; Lerner D; Goldenberg W; Miskolczi I; Molnar S; Rantal F; Tamas T; Toth G; Zagyva A; Zekany A; Finberg J; Lavian G; Gross A; Friedman R; Razin M; Huang W; Krais B; Chorev M; Youdim MB; Weinstock M
J Med Chem; 2002 Nov; 45(24):5260-79. PubMed ID: 12431053
[TBL] [Abstract][Full Text] [Related]
2. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Samadi A; de los Ríos C; Bolea I; Chioua M; Iriepa I; Moraleda I; Bartolini M; Andrisano V; Gálvez E; Valderas C; Unzeta M; Marco-Contelles J
Eur J Med Chem; 2012 Jun; 52():251-62. PubMed ID: 22503231
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Bolea I; Juárez-Jiménez J; de Los Ríos C; Chioua M; Pouplana R; Luque FJ; Unzeta M; Marco-Contelles J; Samadi A
J Med Chem; 2011 Dec; 54(24):8251-70. PubMed ID: 22023459
[TBL] [Abstract][Full Text] [Related]
4. Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: Synthesis, biological evaluation and docking study.
Krátký M; Vu QA; Štěpánková Š; Maruca A; Silva TB; Ambrož M; Pflégr V; Rocca R; Svrčková K; Alcaro S; Borges F; Vinšová J
Bioorg Chem; 2021 Nov; 116():105301. PubMed ID: 34492558
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Xu YX; Wang H; Li XK; Dong SN; Liu WW; Gong Q; Wang TD; Tang Y; Zhu J; Li J; Zhang HY; Mao F
Eur J Med Chem; 2018 Jan; 143():33-47. PubMed ID: 29172081
[TBL] [Abstract][Full Text] [Related]
6. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
Wang L; Esteban G; Ojima M; Bautista-Aguilera OM; Inokuchi T; Moraleda I; Iriepa I; Samadi A; Youdim MB; Romero A; Soriano E; Herrero R; Fernández Fernández AP; Ricardo-Martínez-Murillo ; Marco-Contelles J; Unzeta M
Eur J Med Chem; 2014 Jun; 80():543-61. PubMed ID: 24813882
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Bautista-Aguilera OM; Esteban G; Bolea I; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Samadi A; Soriano E; Unzeta M; Marco-Contelles J
Eur J Med Chem; 2014 Mar; 75():82-95. PubMed ID: 24530494
[TBL] [Abstract][Full Text] [Related]
8. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Bautista-Aguilera OM; Esteban G; Chioua M; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Soriano E; Samadi A; Unzeta M; Marco-Contelles J
Drug Des Devel Ther; 2014; 8():1893-910. PubMed ID: 25378907
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of pyrano[4,3-b][1]benzopyranone derivatives as monoamine oxidase and cholinesterase inhibitors.
Takao K; Kubota Y; Kamauchi H; Sugita Y
Bioorg Chem; 2019 Mar; 83():432-437. PubMed ID: 30428433
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease.
Li F; Wang ZM; Wu JJ; Wang J; Xie SS; Lan JS; Xu W; Kong LY; Wang XB
J Enzyme Inhib Med Chem; 2016; 31(sup3):41-53. PubMed ID: 27384289
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, biological activity, molecular docking, and molecular dynamics of novel benzimidazole derivatives as potential AChE/MAO-B dual inhibitors.
Osmaniye D; Evren AE; Sağlık BN; Levent S; Özkay Y; Kaplancıklı ZA
Arch Pharm (Weinheim); 2022 Mar; 355(3):e2100450. PubMed ID: 34931332
[TBL] [Abstract][Full Text] [Related]
12. 4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
Kumar B; Dwivedi AR; Sarkar B; Gupta SK; Krishnamurthy S; Mantha AK; Parkash J; Kumar V
ACS Chem Neurosci; 2019 Jan; 10(1):252-265. PubMed ID: 30296051
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer's disease agents.
Yun Y; Yang J; Miao Y; Wang X; Sun J
Bioorg Med Chem Lett; 2020 Feb; 30(4):126900. PubMed ID: 31882295
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 4-substituted benzyl-2-triazole-linked-tryptamine-paeonol derivatives and evaluation of their selective inhibitions against butyrylcholinesterase and monoamine oxidase-B.
Oh JM; Kang Y; Hwang JH; Park JH; Shin WH; Mun SK; Lee JU; Yee ST; Kim H
Int J Biol Macromol; 2022 Sep; 217():910-921. PubMed ID: 35908673
[TBL] [Abstract][Full Text] [Related]
15. Searching for Multi-Targeting Neurotherapeutics against Alzheimer's: Discovery of Potent AChE-MAO B Inhibitors through the Decoration of the 2H-Chromen-2-one Structural Motif.
Pisani L; Farina R; Soto-Otero R; Denora N; Mangiatordi GF; Nicolotti O; Mendez-Alvarez E; Altomare CD; Catto M; Carotti A
Molecules; 2016 Mar; 21(3):362. PubMed ID: 26999091
[TBL] [Abstract][Full Text] [Related]
16. Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Yang X; Qiang X; Li Y; Luo L; Xu R; Zheng Y; Cao Z; Tan Z; Deng Y
Bioorg Chem; 2017 Apr; 71():305-314. PubMed ID: 28267984
[TBL] [Abstract][Full Text] [Related]
17. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
18. Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity.
Yu PH; Davis BA; Boulton AA
Biochem Pharmacol; 1993 Aug; 46(4):753-7. PubMed ID: 8363648
[TBL] [Abstract][Full Text] [Related]
19. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
Youdim MB; Weinstock M
Mech Ageing Dev; 2002 Apr; 123(8):1081-6. PubMed ID: 12044957
[TBL] [Abstract][Full Text] [Related]
20. N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.
Košak U; Strašek N; Knez D; Jukič M; Žakelj S; Zahirović A; Pišlar A; Brazzolotto X; Nachon F; Kos J; Gobec S
Eur J Med Chem; 2020 Jul; 197():112282. PubMed ID: 32380361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
